News in Brief: AL amyloidosis trials due this year; New blood product labelling standard cuts supply time by 75%; Extra COVID-19 surveillance in HSCT patients needed

AL amyloidosis trials due this year Two trials are set to investigate new treatment regimens for newly diagnosed patients with AL amyloidosis with moderate to severe cardiac disease. Both Phase III trials will look at standard therapy for AL – VCD (Velcade®, cyclophosphamide and dexamethasone) — plus either birtamimab  or CAEL-101, which are monoclonal antibodies ...

Already a member?

Login to keep reading.

© 2021 the limbic